A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: May 22, 2008
Last updated: September 21, 2015
Last verified: September 2015
This study was conducted: 1) to assess the clinical effect of Navarixin on the Psoriasis Activity and Severity Index (PASI), 2) to determine the effects of Navarixin on the Physician's Global Assessment (PGA), 3) to evaluate the safety and tolerability of Navarixin, and 4) to determine the multiple-dose pharmacokinetics of Navarixin.
Drug: Navarixin 10 mg
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
||A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis
Primary Outcome Measures:
- Mean Percent Change From Baseline in the Psoriasis and Activity Severity Index (PASI) Score at Day 29 [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
PASI score is a means to qualify the extent and severity of psoriatic lesions. The total score is calculated as the sum of the extent and severity of lesions on the head, arms, trunk, and legs and the score can range from 0 (no symptoms) to 72 (maximum symptoms).
Secondary Outcome Measures:
- Number of Participants by Physician's Assessment of Global Improvement (PGA) Score At Day 29 [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
The PGA is a questionnaire that asks the treating physician to rate the participant's signs and symptoms on a scale where 0=worse, 1=unchanged, 2= slight improvement, 3= fair improvement, 4= good improvement, 5= excellent improvement, and 6=cleared, with higher scores indicating better outcomes.
- Mean Maximum Plasma Concentration (Cmax) of Navarixin at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
Participant blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours following oral administration of Navarixin to determine the mean Cmax at Day 28. Blood samples were not collected from the placebo group to evaluate this endpoint.
- Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC [0-24]) of Navarixin at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
Participant blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours following oral administration of Navarixin to determine the mean AUC(0-24) at Day 28. Blood samples were not collected from the placebo group to evaluate this endpoint.
- Mean Terminal Phase Half-life (T1/2) of Navarixin at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
Participant blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours to determine the mean T1/2 of Navarixin following oral administration at Day 28. Blood samples were not collected from the placebo group to evaluate this endpoint.
- Median Time to Maximum Plasma Concentration (Tmax) of Navarixin at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
Participant blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours following oral administration of Navarixin to determine the Mean Tmax at Day 28. Blood samples were not collected from the placebo group to evaluate this endpoint.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2007 (Final data collection date for primary outcome measure)
Navarixin 30 mg administered orally once daily for 28 days.
Drug: Navarixin 10 mg
Navarixin capsules orally, once daily for 28 days.
Placebo Comparator: Placebo
Matching placebo to Navarixin administered orally once daily for 28 days.
Matching placebo capsules to Navarixin orally, once daily for 28 days.
|Ages Eligible for Study:
||18 Years to 70 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Body Mass Index (BMI) 19 to 34, BMI = weight (kg)/height (m^2).
- Must have a diagnosis of psoriasis vulgaris (PASI >8) present for at least 1 year. Participants with an on-therapy PASI <=8 at Screening may be considered for inclusion. Participants must be discussed with the Sponsor prior to enrollment and the subject must have indicated that they are not satisfied with current therapy. To be included, participants must have a PASI >8 following washout of their current psoriasis therapy.
- Target lesion selected must be located on the head, trunk, arms or legs and be at least 10 cm^2 in size. The lesion's total numerical ratings for erythema, infiltration, and desquamation must be at least 6 out of the possible 12. Severity score for desquamation must be at least 2.
- Vital sign measurements (taken after ~3 minutes in a supine position) must be within the following ranges: oral body temperature between 35.0°C to 37.5°C; systolic blood pressure, 90 to 160 mm Hg; diastolic blood pressure, 45 to 90 mm Hg; pulse rate, 40 to 100 bpm.
- Have stable disease (ie, off treatment PASI during Screening period and Baseline PASI should not differ by more than 40%).
- Clinical laboratory tests (CBC, blood chemistries, and urinalysis) must be within normal limits or clinically acceptable to the investigator/sponsor. Participants must have a neutrophil count of at least 2 x 10^9/L to be included.
- Free of any clinically significant disease (other than psoriasis).
- Willing to give written informed consent and able to adhere to dose and visit schedules.
- For female participants: Negative serum pregnancy test (beta-hCG) and urine pregnancy test. Agree to use medically accepted methods of contraception during and for an appropriate pre-study period while receiving protocol specified medication, and for 1 month after stopping medication. Female participants of non-childbearing potential must be surgically sterilized or be postmenopausal.
- Male subject must agree to use an adequate form of contraception for the duration of the study.
- At Screening, ECG conduction intervals must be within gender specific normal range (ie, QTc for males <430 msec and females <450 msec) or if not within the normal range, the values must be considered clinically insignificant by the investigator and sponsor.
- Female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breastfeeding.
- Participants who, in the opinion of the investigator, will not be able to participate optimally in the study.
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug.
- History of any infectious disease within 4 weeks prior to drug administration and/or are positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
- Immunocompromised participants.
- Positive screen for drugs with a high potential for abuse or have a history of drug or alcohol abuse in the past 2 years.
- History of mental instability or who have been treated for mood disorders.
- Donated blood in the past 60 days.
- Previous treatment with study medication.
- Currently participating in another clinical study or have participated in a clinical study within 30 days.
- Part of the study staff personnel or family members of the study staff personnel.
- Demonstrated clinically significant (requiring intervention) allergic reactions or who are known to be allergic to components of local anesthetics.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00684593
Merck Sharp & Dohme Corp.
||Merck Sharp & Dohme Corp.
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
||P04481, 2006-006601-83, P04481
|Study First Received:
||May 22, 2008
|Results First Received:
||September 26, 2014
||September 21, 2015
||Denmark: Danish Medicines Agency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 13, 2015
Skin Diseases, Papulosquamous